Evidence map›Paper›PMID 39061890›Full record

ArticleAntioxidants (Basel, Switzerland)2024

Differential Effects of Three Medium-Chain Fatty Acids on Mitochondrial Quality Control and Skeletal Muscle Maturation.

Ryoichi Nishida, Shota Nukaga, Isao Kawahara, Yoshihiro Miyagawa, Kei Goto, Chie Nakashima, Yi Luo, Takamitsu Sasaki, Kiyomu Fujii, Hitoshi Ohmori and 4 more

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ryoichi NishidaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.ORCID 0009-0008-6517-8420
Shota NukagaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Isao KawaharaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Yoshihiro MiyagawaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Kei GotoDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Chie NakashimaDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Yi LuoDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Takamitsu SasakiDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Kiyomu FujiiDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Hitoshi OhmoriDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Ruiko OgataDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Shiori MoriDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Rina Fujiwara-TaniDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.
Hiroki KuniyasuDepartment of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Japan.ORCID 0000-0003-2298-8825

Funding

Ministry of Education, Culture, Sports, Science and Technology 19K16564Ministry of Education, Culture, Sports, Science and Technology 20K21659Ministry of Education, Culture, Sports, Science and Technology 21K06926Ministry of Education, Culture, Sports, Science and Technology 22K11423Ministry of Education, Culture, Sports, Science and Technology 22K17655Ministry of Education, Culture, Sports, Science and Technology 23K16547
6 · The paper itself

Abstract

Nutritional interventions are one focus of sarcopenia treatment. As medium-chain fatty acids (MCFAs) are oxidized in the mitochondria and produce energy through oxidative phosphorylation (OXPHOS), they are key parts of nutritional interventions. We investigated the in vitro effects of three types of MCFA, caprylic acid (C8), capric acid (C10), and lauric acid (C12), in skeletal muscle cells. Compared with C10 and C12, C8 promoted mitophagy through the phosphatase and tensin homolog (PTEN)-induced kinase 1-Parkin pathway and increased the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α and dynamin-related protein 1 to reduce mitochondrial oxidative stress and promote OXPHOS. Furthermore, the expression of myogenic differentiation 1 and myosin heavy chain increased in myotubes, thus promoting muscle differentiation and maturation. These results suggest that C8 improves mitochondrial quality and promotes skeletal muscle maturation; in contrast, C10 and C12 poorly promoted mitochondrial quality control and oxidative stress and suppressed energy production. Future animal experiments are required to establish the usefulness of C8 for nutritional interventions for sarcopenia.

Indexed as

medium-chain fatty acidsmitochondrial quality controlmitophagyreactive oxygen speciesskeletal muscle

Identifiers

PMID39061890
PMCPMC11273902

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.